CAMBREX CORP (CBM) [Rocket]

Overview

CAMBREX CORP (CBM)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
04/07/2020	GN	Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility
02/10/2020	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/16/2019	15-12B	Form 15-12B - Securities registration termination [Section 12(b)]:
12/06/2019	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/06/2019	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/06/2019	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/06/2019	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
Revenues	532.1	534.5	490.6	433.3	374.6	318.2	276.5	255.7
Revenue growth	-0.4%	8.9%	13.2%	15.7%	17.7%	15.1%	8.2%	12.6%
Cost of goods sold	335.4	304.2	286.3	256.4	250.8	215.3	186.0	181.6
Gross profit	196.7	230.3	204.4	177.0	123.8	102.9	90.5	74.1
Gross margin	37.0%	43.1%	41.7%	40.8%	33.0%	32.3%	32.7%	29.0%
Selling, general and administrative	68.5	69.0	58.0	57.9	52.5	47.6	45.2	39.2
Research and development	15.5	16.9	14.3	12.5	13.1	10.4	9.5	11.0
EBITA	107.2	146.3	133.4	107.4	47.0	42.9	34.2	25.7
EBITA margin	20.1%	27.4%	27.2%	24.8%	12.5%	13.5%	12.4%	10.1%
Amortization of intangibles	5.7	1.9	1.0	0.9	0.5	0.3	0.2	0.3
EBIT	101.5	144.4	132.4	106.6	46.4	42.7	33.9	25.4
EBIT margin	19.1%	27.0%	27.0%	24.6%	12.4%	13.4%	12.3%	10.0%
Pre-tax income	109.8	141.8	127.5	89.6	45.5	45.0	31.4	19.9
Income taxes	16.6	38.1	40.2	32.4	-12.6	14.7	-31.9	6.2
Tax rate	15.1%	26.8%	31.5%	36.2%		32.7%		31.1%
Net income	92.4	102.5	81.7	57.2	57.3	25.9	62.3	11.0
Net margin	17.4%	19.2%	16.6%	13.2%	15.3%	8.1%	22.5%	4.3%

Diluted EPS	$2.77	$3.10	$2.65	$1.76	$1.84	$0.98	$2.09	$0.46
Shares outstanding (diluted)	33.7	33.5	33.0	32.6	31.6	30.9	30.3	29.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.